Rani nabs $69M Se­ries E for its stab at a ro­bot­ic pill to re­place in­jectable drugs

5 years ago
Financing

Mar­ry­ing pre­ci­sion med and AI, Groupon co-founder Er­ic Lefkof­sky takes to­tal haul for his an­a­lyt­ics firm over the $1B ...

5 years ago
Financing

De­spite flop­ping piv­otal tri­al, No­var­tis' En­tresto will face ad­comm fir­ing line for holy grail heart fail­ure pa­tients

5 years ago
Pharma
FDA+

Savara shuts down an­oth­er cys­tic fi­bro­sis pro­gram af­ter a PhI­II flop, as it pre­pares to axe staff and re-cen­ter ...

5 years ago
R&D

Look­ing for an edge in vac­cines, Ther­mo Fish­er plots ma­jor ex­pan­sions across glob­al man­u­fac­tur­ing sites in its ...

5 years ago
Outsourcing
Manufacturing

An EUA is com­ing, FDA tells Pfiz­er

5 years ago
FDA+
Coronavirus

No­var­tis’ $9.7B PC­SK9 drug nabs first OK — now comes the chal­lenge of find­ing a mar­ket

5 years ago
FDA+

2020's IPO par­ty con­tin­ues with four new Nas­daq en­trants, in­clud­ing Cov­il­lion­aire Carl Hansen's Ab­Cellera

5 years ago
Financing

Covid-19 roundup: As­traZeneca team finds a sur­prise Covid-19 vac­cine part­ner; Bio­gen con­fer­ence linked to 300K cas­es

5 years ago
Coronavirus

Sanofi, Glax­o­SmithK­line hit with a ma­jor de­lay on Covid-19 vac­cine pro­gram as their first jab flops in old­er adults

5 years ago
R&D
Coronavirus

Ad­vi­so­ry com­mit­tee votes 17-4 to rec­om­mend FDA au­tho­rize Pfiz­er-BioN­Tech vac­cine, open­ing door to rapid EUA

5 years ago
FDA+
Coronavirus

Sanofi ac­cepts a lengthy de­lay as its he­mo­phil­ia drug fi­tusir­an re­sumes a PhI­II af­ter safe­ty fears forced a halt

5 years ago
R&D
FDA+

Uni­ver­si­ty of Queens­land shuts down Covid-19 vac­cine pro­gram af­ter ob­serv­ing in­ter­fer­ence with HIV tests

5 years ago
Coronavirus

News brief­ing: Tri­al soft­ware firm ERT merges with imag­ing com­pa­ny Bio­clin­i­ca; Ab­Cellera bumps IPO range

5 years ago
News Briefing

Re­call re­port: AvKARE some­how mixed its an­ti­de­pres­sant and erec­tile dys­func­tion meds; Tor­rent pulls throm­bo­cy­to­sis ...

5 years ago
Pharma
FDA+

An­gling for a spot among the gi­ants, TG Ther­a­peu­tics touts PhI­II MS da­ta for CD20 drug

5 years ago
R&D

Long­time In­ter­cept CEO Mark Pruzan­s­ki de­parts as ail­ing NASH com­pa­ny tries to find its fu­ture

5 years ago
People

Alk­er­mes CEO Richard Pops wins over ac­tivists with a pledge to shake up the com­pa­ny and boost net in­come

5 years ago
Pharma

New York law­suit again ac­cus­es Mar­tin Shkre­li of ma­nip­u­la­tion from be­hind bars

5 years ago
People
Pharma

Boehringer In­gel­heim buys out next-gen ADC play­er NBE-Ther­a­peu­tics in a deal worth up to $1.4B+

5 years ago
Deals

'Are you guys out of vi­rol­o­gy?': Not hard­ly, says Gilead ex­ecs, as they buy a late-stage drug com­pa­ny for $1.7B

5 years ago
Deals

Covid-19 roundup: Mod­er­na be­gins PhII/III vac­cine study in ado­les­cents; Pfiz­er and BioN­Tech's vac­cine gets an OK in ...

5 years ago
Coronavirus

Faze Med­i­cines launch­es with $81M Se­ries A, Al­ny­lam vet head­ing sci­ence in play at bio­mol­e­c­u­lar con­den­sates

5 years ago
Financing
Startups

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women blaz­ing trails in bio­phar­ma R&D — Covid-19 and be­yond

5 years ago
People
Special
First page Previous page 767768769770771772773 Next page Last page
A service from the Financial Times